Premium
O4‐07‐08: Design of selective estrogen receptor modulators as neuroprotective and procognitive agents
Author(s) -
Thatcher Gregory R.J.,
Abdelhamid Ramy,
Luo Jia,
Qin Zhihui
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.511
Subject(s) - selective estrogen receptor modulator , neuroprotection , raloxifene , pharmacology , estrogen receptor , estrogen , chemistry , medicine , endocrinology , cancer , breast cancer
(OR 0.28 [95% CI, 0.10-0.80] for dementia; OR 0.58 [95% CI, 0.38-0.89] for cognitive impairment) and among normal-weight men (OR 0.34 [95% CI, 0.14-0.83] for dementia and OR 0.56 [95% CI, 0.37-0.84] for cognitive impairment). The low-risk profile was associated with a decreased OR for dementia (OR 0.38 [95% CI, 0.19-0.77]) among men without the APOE e4 allele, but not among men with 1 or 2 alleles. Conclusions: In this population, having a healthy lifestyle in midlife reduced the risk of dementia in late life.